Neoadjuvant chemotherapy and primary-first approach for rectal cancer with synchronous liver metastases

Colorectal Disease

Volumn 16, Issue 6, 2014, Pages

  Gall, T M H ^a   Basyouny, M ^a   Frampton, A E ^a   Darzi, A ^b   Ziprin, P ^b   Dawson, P ^b   Paraskeva, P ^b   Habib, N A ^a   Spalding, D R C ^a   Cleator, S ^c   Lowdell, C ^c   Jiao, L R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Neoadjuvant; Primary first; Rectal cancer; Synchronous liver metastases

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECTUM CANCER; RECTUM RESECTION; ADJUVANT THERAPY; CANCER STAGING; COLON RESECTION; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; PROCEDURES; RECTAL NEOPLASMS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLECTOMY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84900514011     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12534     Document Type: Article

References (28)

1. Downing A, Aravani A, Macleod U et al. Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in the first year after diagnosis. Br J Cancer 2013; 108: 681-5.
2. Micheli A, Mugno E, Krogh V et al. Cancer prevalence in European registry areas. Ann Oncol 2002; 13: 840-65.
3. Mantke R, Schmidt U, Wolff S et al. Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study. Eur J Surg Oncol 2012; 38: 259-65.
4. Scheele J, Stang R, Altendorf-Hofmann A et al. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
5. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-18; discussion 318-21.
6. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-46.
7. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811-20.
8. Marijnen CA, Nagtegaal ID, Kapiteijn E et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55: 1311-20.
9. Bosset JF, Calais G, Mineur L et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results - EORTC 22921. J Clin Oncol 2005; 23: 5620-7.
10. Sauer R, Liersch T, Merkel S et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33.
11. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-6.
12. Dewdney A, Cunningham D, Barbachano Y et al. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer 2012; 106: 1718-21.
13. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
14. Boostrom SY, Vassiliki LT, Nagorney DM et al. Synchronous rectal and hepatic resection of rectal metastatic disease. J Gastrointest Surg 2011; 15: 1583-8.
15. Thelen A, Jonas S, Benckert C et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis 2007; 22: 1269-76.
16. Mentha G, Majno PE, Andres A et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006; 93: 872-8.
17. van der Pool AE, de Wilt JH, Lalmahomed ZS et al. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg 2010; 97: 383-90.
18. Verhoef C, van der Pool AE, Nuyttens JJ et al. The 'liver-first approach' for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 2009; 52: 23-30.
19. Mann CD, Metcalfe MS, Leopardi LN et al. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 2004; 139: 1168-72.
20. Tsim N, Healey AJ, Frampton AE et al. Two-stage resection for bilobar colorectal liver metastases: R0 resection is the key. Ann Surg Oncol 2011; 18: 1939-46.
21. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-57; discussion 657-8.
22. Lam VW, Spiro C, Laurence JM et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 2012; 19: 1292-301.
23. Seshimo K, Oishi M, Toshima T et al. [A case of resected rectal cancer with hepatic node and multiple liver metastases effectively treated by preoperative modified FOLFOX6 and sLV5FU2 chemotherapy]. Gan To Kagaku Ryoho 2012; 39: 477-80.
24. Deguchi Y, Endo S, Tanaka J et al. [A case of resection of synchronous multiple liver metastases from rectal cancer after FOLFOX4 therapy]. Gan To Kagaku Ryoho 2010; 37: 1159-62.
25. Inoue M, Uehara K, Ishiguro S et al. [Pathologically complete response of multiple liver metastases from rectal cancer treated with mFOLFOX6 plus bevacizumab]. Nihon Shokakibyo Gakkai Zasshi 2010; 107: 760-7.
26. De RA, Gomez D, Brooks A et al. 'Liver-first' approach for synchronous colorectal liver metastases: is this a justifiable approach? J Hepatobiliary Pancreat Sci 2013; 20: 263-70.
27. Andres A, Toso C, Adam R et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg 2012; 256: 772-8; discussion 778-9.
28. Ayez N, Burger JW, van der Pool AE et al. Long-term results of the 'liver first' approach in patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 2013; 56: 281-7.